Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
53 hedge funds and large institutions have $121M invested in Clearside Biomedical in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 28 increasing their positions, 10 reducing their positions, and 13 closing their positions.
180% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 10
27% more capital invested
Capital invested by funds: $95.2M → $121M (+$25.8M)
0.34% more ownership
Funds ownership: 3.16% → 3.5% (+0.34%)
10% less funds holding
Funds holding: 59 → 53 (-6)
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.73M |
| 2 |
BlackRock
New York
|
+$4M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.04M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$863K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$738K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$2.38M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.39M |
| 3 |
NC
Nexthera Capital
New York
|
-$959K |
| 4 |
PA
Perceptive Advisors
New York
|
-$736K |
| 5 |
PP
PDT Partners
New York
|
-$534K |
CLSD Hedge Fund Activity: Q2 2017 in Review
53 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2017, worth a combined $121M — up 27% from $95.2M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CLSD and 7 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 28 added.
The largest buyer was Wellington Management Group, adding an estimated $5.73M. The largest seller was OrbiMed, exiting entirely with an estimated $2.38M sold.
- 53 institutional investors held Clearside Biomedical (CLSD) as of Q2 2017, down from 59 in Q1 2017.
- Funds reported $121M of Clearside Biomedical stock for Q2 2017, up 27% quarter-over-quarter.
- 7 funds opened new Clearside Biomedical positions in Q2 2017 and 13 closed out, a net change of -6 holders.
- The largest Clearside Biomedical buyer in Q2 2017 was Wellington Management Group, an estimated $5.73M added.
- The largest Clearside Biomedical seller in Q2 2017 was OrbiMed, an estimated $2.38M sold.
Based on aggregated 13F filings for Q2 2017.